Combined Biomimetic MOF-RVG15 Nanoformulation Efficient Over BBB for Effective Anti-Glioblastoma in Mice Model
Hao Wu,Yanhong Liu,Liqing Chen,Shuangqing Wang,Chao Liu,Heming Zhao,Mingji Jin,Shuangyan Chang,Xiuquan Quan,Minhu Cui,Hongshuang Wan,Zhonggao Gao,Wei Huang
DOI: https://doi.org/10.2147/ijn.s387715
IF: 7.033
2022-12-15
International Journal of Nanomedicine
Abstract:Hao Wu, 1, 2 Yanhong Liu, 2 Liqing Chen, 2 Shuangqing Wang, 1, 2 Chao Liu, 2 Heming Zhao, 2 Mingji Jin, 1, 2 Shuangyan Chang, 2 Xiuquan Quan, 3 Minhu Cui, 3 Hongshuang Wan, 2, 3 Zhonggao Gao, 1, 2 Wei Huang 2 1 Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin Province, 133002, People's Republic of China; 2 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, People's Republic of China; 3 Department of Gastroenterology, Yanbian University Hospital, Yanji, Jilin Province, 133000, People's Republic of China Correspondence: Zhonggao Gao; Wei Huang, Tel +86 10 63028096 ; +86 10 63026505, Email ; Introduction: The blood–brain barrier (BBB) is a key obstacle to the delivery of drugs into the brain. Therefore, it is essential to develop an advanced drug delivery nanoplatform to solve this problem. We previously screened a small rabies virus glycoprotein 15 (RVG 15 ) peptide with 15 amino acids and observed that most of the RVG 15 -modified nanoparticles entered the brain within 1 h of administration. The high BBB penetrability gives RVG 15 great potential for brain-targeted drug delivery systems. Moreover, a multifunctional integrated nanoplatform with a high drug-loading capacity, tunable functionality, and controlled drug release is crucial for tumor treatment. Zeolitic imidazolate framework (ZIF-8) is a promising nanodrug delivery system. Methods: Inspired by the biomimetic concept, we designed RVG 15 -coated biomimetic ZIF-8 nanoparticles (RVG 15 @ZIF-8) for docetaxel (DTX) delivery to achieve efficient glioblastoma elimination in mice. This bionic nanotherapeutic system was prepared by one-pot encapsulation, followed by coating with RVG 15 -PEG conjugates. The size, morphology, stability, drug-loading capacity, and release of RVG 15 @ZIF-8 were thoroughly investigated. Additionally, we performed in vitro evaluation, cell uptake capacity, BBB penetration, and anti-migratory ability. We also conducted an in vivo evaluation of the biodistribution and anti-glioma efficacy of this bionic nanotherapeutic system in a mouse mode. Results: In vitro studies showed that, this bionic nanotherapeutic system exhibited excellent targeting efficiency and safety in HBMECs and C6 cells and high efficiency in crossing the BBB. Furthermore, the nanoparticles cause rapid DTX accumulation in the brain, allowing deeper penetration into glioma tumors. In vivo antitumor assay results indicated that RVG 15 @ZIF-8 significantly inhibited glioma growth and metastasis, thereby improving the survival of tumor-bearing mice. Conclusion: Our study demonstrates that our bionic nanotherapeutic system using RVG 15 peptides is a promising and powerful tool for crossing the BBB and treating glioblastoma. Keywords: glioblastoma, blood–brain barrier, RVG15, biomimetic nanoparticle, zeolitic imidazolate frameworks-8, ZIF-8 Glioma, the most common malignant brain tumor, is recognized as an incurable and deadly forms of cancer. According to a report by the International Agency for Research on Cancer, 308,102 new brain tumors diagnoses resulted in 251,329 deaths worldwide in 2020. 1 Glioblastoma (GBM) is the most rapidly progressing subtype of glioma, with a 5-year survival rate of 5.6%. 2,3 Surgery is the primary treatment for GBM. 4–6 However, it is often difficult to achieve complete resection of the tumor while preserving neurological function. Therefore, chemotherapy is crucial in GBM treatment. Several advanced therapeutic drugs, including immune-activating, small molecule targeted, and antibody drugs, have been successful in other malignant tumors. 7–9 Unfortunately, the blood–brain barrier (BBB) and blood–brain–tumor barrier (BBTB) restrict the current drugs from entering the brain for effective GBM treatment. 10 Therefore, many therapeutic agents that are effective against glioma cells in vitro exhibit lower response in vivo. With advances in nanotechnology and associated molecular biology, numerous strategies have been developed to surpass the BBB and BBTB, including ultrasound or thermal-induced BBB disruption, receptor-mediated transport systems, tight junctions opening, and absorption-mediated transcytosis. 11–13 Nevertheless, these methods allow limit -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology